Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype
- PMID: 10700538
- DOI: 10.1053/ejpn.1999.0181
Very severe spinal muscular atrophy (SMA type 0): an expanding clinical phenotype
Abstract
The classical form of severe spinal muscular atrophy (SMA type 1; Werdnig-Hoffmann disease) has a very consistent clinical phenotype that is well recognized by paediatricians. It usually presents at birth or within the first few months of life. There is general hypotonia, with axial and limb weakness; the legs are affected more than the arms and proximal muscles more than distal, leaving residual spontaneous activity in the feet and in the forearms and hands. Facial muscles are spared so that the infant usually has a bright normal expression. The intercostal muscles are always affected, whereas the diaphragm is spared, allowing adequate spontaneous respiratory activity until the infants are precipitated into respiratory failure by an incidental respiratory infection, or aspiration. With rare exception they die by 2 years of age with a median around 7 months and with about 80% of the children dying by the time they are 1 year old. There is a consistent homozygous deletion in exons 7 and 8 of the telomeric copy of the survival motor neuron (SMN) gene. In the current issue of the journal, MacLeod and her colleagues have documented five cases of more severe spinal muscular atrophy, with a history of diminished fetal movements in utero and presenting at birth with asphyxia and severe weakness.
Copyright 1999 European Paediatric Neurology Society.
Comment on
-
Prenatal onset spinal muscular atrophy.Eur J Paediatr Neurol. 1999;3(2):65-72. doi: 10.1053/ejpn.1999.0184. Eur J Paediatr Neurol. 1999. PMID: 10700541
Similar articles
-
Prenatal onset spinal muscular atrophy.Eur J Paediatr Neurol. 1999;3(2):65-72. doi: 10.1053/ejpn.1999.0184. Eur J Paediatr Neurol. 1999. PMID: 10700541
-
Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling.Clin Genet. 2009 Aug;76(2):168-78. doi: 10.1111/j.1399-0004.2009.01200.x. Clin Genet. 2009. PMID: 19780763
-
[Neonatal muscular spinal atrophy: a case report].Pediatr Med Chir. 2004 Mar-Apr;26(2):139-41. Pediatr Med Chir. 2004. PMID: 15700740 Italian.
-
Spinal muscular atrophy.Semin Neurol. 1998;18(1):19-26. doi: 10.1055/s-2008-1040858. Semin Neurol. 1998. PMID: 9562664 Review.
-
Clinical and molecular diagnosis of spinal muscular atrophy.Neurol India. 2002 Jun;50(2):117-22. Neurol India. 2002. PMID: 12134171 Review.
Cited by
-
Spinal Muscular Atrophy.Neurol Clin. 2015 Nov;33(4):831-46. doi: 10.1016/j.ncl.2015.07.004. Neurol Clin. 2015. PMID: 26515624 Free PMC article. Review.
-
Preclinical Safety Assessment and Toxicokinetics of Apitegromab, an Antibody Targeting Proforms of Myostatin for the Treatment of Muscle-Atrophying Disease.Int J Toxicol. 2021 Jul-Aug;40(4):322-336. doi: 10.1177/10915818211025477. Int J Toxicol. 2021. PMID: 34255983 Free PMC article.
-
A Comparative Study of SMN Protein and mRNA in Blood and Fibroblasts in Patients with Spinal Muscular Atrophy and Healthy Controls.PLoS One. 2016 Nov 28;11(11):e0167087. doi: 10.1371/journal.pone.0167087. eCollection 2016. PLoS One. 2016. PMID: 27893852 Free PMC article. Clinical Trial.
-
Spinal muscular atrophy - insights and challenges in the treatment era.Nat Rev Neurol. 2020 Dec;16(12):706-715. doi: 10.1038/s41582-020-00413-4. Epub 2020 Oct 14. Nat Rev Neurol. 2020. PMID: 33057172 Review.
-
Molecular Pathogenesis and New Therapeutic Dimensions for Spinal Muscular Atrophy.Biology (Basel). 2022 Jun 10;11(6):894. doi: 10.3390/biology11060894. Biology (Basel). 2022. PMID: 35741415 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
